| Budget Amount *help |
¥24,050,000 (Direct Cost: ¥18,500,000、Indirect Cost: ¥5,550,000)
Fiscal Year 2020: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2019: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥11,960,000 (Direct Cost: ¥9,200,000、Indirect Cost: ¥2,760,000)
|
|---|
| Outline of Final Research Achievements |
Vaccine is one of the most important strategy to prevent infectious diseases. In this study, a solid-in-oil-in-water (S/O/W) emulsion adjuvant was prepared. In the traditional emulsion adjuvant, antigens were added in the outer water phase and were separately delivered to antigen presenting cells. On the other hand, in the S/O/W emulsion adjuvant, antigens were encapsulated in the inner oil phase by solid-in-oil nanodispersion technology. From the vaccine study, the S/O/W emulsion produced the antigen-specific antibody and prevented tumor growth by antigen-specific immune responses compared to the traditional emulsion. This performance was resulted from the property of the S/O/W emulsion that deliver antigens to the antigen presenting cells together with adjuvant. These results suggested that the S/O/W emulsion is the promising vaccine delivery carrier.
|
